May 23, 2007 - EDAP TMS S.A., a developer of High Intensity Focused Ultrasound (HIFU) treatments of prostate cancer recently announced it is fast-tracking its ongoing U.S. Ablatherm-HIFU clinical trial due to results presented at the European Association of Urologists (EAU) in March, 2007.
"We have treated more than 1,800 patients in our center over 10 years and we now have mature data that demonstrates the long-term benefits of Ablatherm-HIFU. Given the success we've had in Europe and the clear consensus from urologists that this therapy is a good selection for patients, it is a priority to make this leading-edge, noninvasive treatment available in the U.S.," said Christian Chaussy, M.D. Department of Urology, Krankenhaus Muenchen-Harlaching, Germany.
The Ablatherm integrated imaging device is designed to target and deliver high-intensity focused ultrasound (HIFU) energy to the prostate, resulting in thermal destruction of prostate tissue. It is intended for the primary treatment of localized prostate cancer in subjects with low risk, localized prostate cancer.
The focused energy is delivered from an endorectal probe containing ultrasound treatment and imaging transducers. Treatment with HIFU for low risk, localized prostate cancer subjects is expected to result in immediate thermal destruction of prostate tissue.
Source: Medical News Today
July 19, 2024 
